AZ unveils detailed data from THALES trial
The results show a 17% cut in the risk of subsequent stroke in patients taking Brilinta and aspirin
Read More
Tag: ticagrelor
US priority review for AZ’ Brilinta/aspirin combination
Brilinta/aspirin combo could be the first US-approved dual antiplatelet therapy to cut risk of second stroke
Read More
New US approval for AZ’ Brilinta
New Brilinta indication expands treatment to high-risk coronary patients without a history of stroke or heart attack
Read More
AZ enrolls first patient in Brilinta stroke trial
Brilinta (ticagrelor) is approved for the treatment of acute coronary syndromes and prevention of further coronary events in patients at high-risk following a heart attack.
Read More
Extended use of AZ’ Brilinta cuts CV death risk 29%
Long-term use of AstraZeneca’s Brilinta in patients with a history of heart attack reduces the risk of cardiovascular death by 29 percent, a new sub analysis of data from the Phase III PEGASUS-TIMI 54 trial has found.
Read More
NICE backs long-term use of AZ’ Brilique
The National Institute of Health and Care Excellence (NICE) has now published a Final Appraisal Determination recommending a lower dose of AstraZeneca’s anti-clotting treatment Brilique for longer-term use in the prevention of heart attack and stroke.
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
